MX367773B - Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. - Google Patents

Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.

Info

Publication number
MX367773B
MX367773B MX2015005510A MX2015005510A MX367773B MX 367773 B MX367773 B MX 367773B MX 2015005510 A MX2015005510 A MX 2015005510A MX 2015005510 A MX2015005510 A MX 2015005510A MX 367773 B MX367773 B MX 367773B
Authority
MX
Mexico
Prior art keywords
mpeg6
hydroxycodone
alpha
salt form
opioid agonists
Prior art date
Application number
MX2015005510A
Other languages
English (en)
Other versions
MX2015005510A (es
Inventor
Patricia Andres
Yogesh Datar
Ramakrishna Gadiraju
Bruce Andrew Kowalczyk
Gabriel Christian Kuklis
Mahmoud Mirmehrabi
Nicholas Paschalides
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of MX2015005510A publication Critical patent/MX2015005510A/es
Publication of MX367773B publication Critical patent/MX367773B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C07D489/04—Salts; Organic complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Abstract

En la presente se proporcionan formas sólidas de ciertos agonistas opioides; en la presente también se proporcionan métodos para preparar las formas sólidas, métodos para utilizar las formas sólidas y composiciones farmacéuticas que comprenden las formas sólidas.
MX2015005510A 2012-10-30 2013-10-29 Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos. MX367773B (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261720259P 2012-10-30 2012-10-30
US201361791894P 2013-03-15 2013-03-15
PCT/US2013/067273 WO2014070745A1 (en) 2012-10-30 2013-10-29 Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Publications (2)

Publication Number Publication Date
MX2015005510A MX2015005510A (es) 2015-09-07
MX367773B true MX367773B (es) 2019-09-05

Family

ID=49674367

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2015005510A MX367773B (es) 2012-10-30 2013-10-29 Forma salina sólida de la alfa-6-mpeg6-o-hidroxicodona como agonistas opioides y sus usos.

Country Status (23)

Country Link
US (2) US9682988B2 (es)
EP (2) EP2914599B1 (es)
JP (2) JP6384964B2 (es)
KR (1) KR20150076175A (es)
CN (2) CN110615796A (es)
AU (2) AU2013338098B2 (es)
CA (1) CA2886276A1 (es)
CY (1) CY1119871T1 (es)
DK (1) DK2914599T3 (es)
EA (1) EA029512B1 (es)
ES (1) ES2651689T3 (es)
HK (2) HK1213549A1 (es)
HR (1) HRP20180315T1 (es)
HU (1) HUE038161T2 (es)
IL (1) IL238529A0 (es)
LT (1) LT2914599T (es)
ME (1) ME02971B (es)
MX (1) MX367773B (es)
PL (1) PL2914599T3 (es)
PT (1) PT2914599T (es)
RS (1) RS56898B1 (es)
SI (1) SI2914599T1 (es)
WO (1) WO2014070745A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10512644B2 (en) * 2007-03-12 2019-12-24 Inheris Pharmaceuticals, Inc. Oligomer-opioid agonist conjugates
WO2014070745A1 (en) * 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof
CA3071261A1 (en) * 2017-07-27 2019-01-31 Inheris Biopharma, Inc. Oral tablet formulations

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5800334A (en) 1993-06-17 1998-09-01 Wilk; Peter J. Intrapericardial assist device and associated method
US6096337A (en) 1996-06-10 2000-08-01 Spireas; Spiridon Liquisolid systems and methods of preparing same
ES2341510T3 (es) 1998-08-13 2010-06-21 Cima Labs Inc. Microemulsiones como formas farmaceuticas solidas para la administracion oral.
US6342249B1 (en) 1998-12-23 2002-01-29 Alza Corporation Controlled release liquid active agent formulation dosage forms
WO2002081477A1 (fr) * 2001-03-30 2002-10-17 Toray Industries, Inc. Derives morphinane 7-substitues et leur utilisation medicinale
WO2002080918A1 (fr) * 2001-04-02 2002-10-17 Toray Industries, Inc. Agent therapeutique ou prophylactique en cas de miction frequente ou d'incontinence urinaire
PT1436012T (pt) 2001-10-18 2018-03-27 Nektar Therapeutics Conjugados poliméricos de antagonistas de opióides
JP2005053744A (ja) 2003-08-05 2005-03-03 Dsl Japan Co Ltd 高吸油性非晶質シリカ粒子
US20050245557A1 (en) * 2003-10-15 2005-11-03 Pain Therapeutics, Inc. Methods and materials useful for the treatment of arthritic conditions, inflammation associated with a chronic condition or chronic pain
NZ572252A (en) 2006-04-21 2011-09-30 Nektar Therapeutics Stereoselective reduction of a morphinone
PT2134371E (pt) * 2007-03-12 2015-04-16 Nektar Therapeutics Conjugados agonistas de opióide-oligómero
US8173666B2 (en) 2007-03-12 2012-05-08 Nektar Therapeutics Oligomer-opioid agonist conjugates
CA2734333A1 (en) 2008-09-16 2010-03-25 Nektar Therapeutics Pegylated opioids with low potential for abuse
KR101788886B1 (ko) * 2009-07-21 2017-10-20 넥타르 테라퓨틱스 올리고머-오피오이드 효능제 컨주게이트
WO2011088140A1 (en) * 2010-01-12 2011-07-21 Nektar Therapeutics Pegylated opioids with low potential for abuse and side effects
DK2621496T4 (en) * 2010-09-30 2019-03-18 Astrazeneca Ab Crystalline NALOXOL-PEG CONJUGATE
EP2606879A1 (en) * 2011-12-21 2013-06-26 Hexal AG Multiple unit pellet tablet formulation comprising an opioid
WO2014070745A1 (en) * 2012-10-30 2014-05-08 Nektar Therapeutics Solid salt form of alpha-6-mpeg6-o-hydroxycodone as opioid agonists and uses thereof

Also Published As

Publication number Publication date
AU2018201297A1 (en) 2018-03-15
EP3327022A1 (en) 2018-05-30
EP2914599A1 (en) 2015-09-09
EA201590853A1 (ru) 2015-08-31
PL2914599T3 (pl) 2018-05-30
US9682988B2 (en) 2017-06-20
KR20150076175A (ko) 2015-07-06
CA2886276A1 (en) 2014-05-08
HRP20180315T1 (hr) 2018-03-23
RS56898B1 (sr) 2018-04-30
CN104755481A (zh) 2015-07-01
HUE038161T2 (hu) 2018-09-28
JP2018111718A (ja) 2018-07-19
HK1248224A1 (zh) 2018-10-12
SI2914599T1 (en) 2018-01-31
US20150284402A1 (en) 2015-10-08
US20170226119A1 (en) 2017-08-10
HK1213549A1 (zh) 2016-07-08
PT2914599T (pt) 2018-01-08
AU2013338098A1 (en) 2015-04-09
CN110615796A (zh) 2019-12-27
MX2015005510A (es) 2015-09-07
CY1119871T1 (el) 2018-06-27
WO2014070745A1 (en) 2014-05-08
ES2651689T3 (es) 2018-01-29
ME02971B (me) 2018-07-20
DK2914599T3 (en) 2017-12-18
LT2914599T (lt) 2018-02-12
JP2015535260A (ja) 2015-12-10
EA029512B1 (ru) 2018-04-30
JP6384964B2 (ja) 2018-09-05
EP2914599B1 (en) 2017-11-22
AU2013338098A8 (en) 2015-05-21
IL238529A0 (en) 2015-06-30
AU2013338098B2 (en) 2018-03-15

Similar Documents

Publication Publication Date Title
MX2016016666A (es) Derivados de acido boronico y usos terapeuticos de los mismos.
TW201231056A (en) Metal salt compositions
MX2016015093A (es) Derivados de acido boronico y sus usos terapeuticos.
MX2013008390A (es) Preparacion de estructuras de metal-triazolato.
PH12016501122A1 (en) Delayed release compositions of linaclotide
MX2016008448A (es) Conjugados de var2csa-farmaco.
GB201106750D0 (en) Novel compounds
WO2012140274A3 (en) Agonists and antagonists of the wnt pathway
MX2015012414A (es) Sal de omecamtiv mecarbilo y proceso para preparar la sal.
GB201106743D0 (en) Novel compounds
AU2013225533A8 (en) Amido spirocyclic amide and sulfonamide derivatives
PH12015500900B1 (en) A stabilized pemetrexed formulation
PH12014501991B1 (en) Phenicol antibacterials
UA115357C2 (uk) Похідні піридин-4-ілу
GEP201706760B (en) Novel abexinostate salt, associated crystalline form, preparation method thereof and the pharmaceutical compositions containing same
MX2015012416A (es) Compuestos heterociclicos y sus usos.
CY1119871T1 (el) Στερεη μορφη αλατος της aλφa-6-mpeg6-o- υδροξυκωδονης ως αγωνιστες οπιοειδων και χρησεις αυτων
MX2015016603A (es) Composiciones de corticosteroides.
WO2014159501A3 (en) Processes for preparing tetrahydroisoquinolines
MX2014004210A (es) Derivados de 2-oxo-piperidinilo.
EP3057972A4 (en) Novel compositions, uses and methods for their preparation
IN2015DN02660A (es)
MX2016001694A (es) Formulacion de vacuna de sacarido.
UA105703C2 (uk) 7-бром-5-феніл-3-ариламіно-1,2-дигідро-3н-1,4-бенздіазепін-2-они як анальгетичні агенти
IN2013CH02437A (es)

Legal Events

Date Code Title Description
FG Grant or registration